Sustained Clinical Response to Immunotherapy Followed by BET Inhibitor in a Patient with Unresectable Sinonasal NUT Carcinoma
NUT carcinomas (NCs) are a group of rare tumors that can occur anywhere in the body and are defined by the fusion of the nuclear protein in testis (NUTM1) resulting in increased transcription of proto-oncogenes. NCs have a poor prognosis that varies according to the site of origin with an urgent nee...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Innovative Healthcare Institute
2024-02-01
|
| Series: | Journal of Immunotherapy and Precision Oncology |
| Subjects: | |
| Online Access: | https://jipo.org/doi/pdf/10.36401/JIPO-23-19 |
| _version_ | 1797316116924596224 |
|---|---|
| author | Harriet Herbison Sidney Davis David Nickless Andrew Haydon Malaka Ameratunga |
| author_facet | Harriet Herbison Sidney Davis David Nickless Andrew Haydon Malaka Ameratunga |
| author_sort | Harriet Herbison |
| collection | DOAJ |
| description | NUT carcinomas (NCs) are a group of rare tumors that can occur anywhere in the body and are defined by the fusion of the nuclear protein in testis (NUTM1) resulting in increased transcription of proto-oncogenes. NCs have a poor prognosis that varies according to the site of origin with an urgent need to develop new treatment strategies. Case reports on immunotherapy in pulmonary NC have been published, and bromodomain and extraterminal (BET) inhibitors have shown activity in NC in phase I/II trials. We present the case of a 27-year-old woman with an unresectable sinonasal NC who had a sustained clinical response to both immunotherapy and BET inhibitor therapy. This is the first reported case of immunotherapy in sinonasal NC, and it highlights the different responses to a range of treatments including BET inhibitor therapy. This case supports the theory that NCs arising from different primary sites have differing prognoses. |
| first_indexed | 2024-03-08T03:14:33Z |
| format | Article |
| id | doaj.art-3cb038dcb4134b309adfab6871b4ee9e |
| institution | Directory Open Access Journal |
| issn | 2666-2345 2590-017X |
| language | English |
| last_indexed | 2024-03-08T03:14:33Z |
| publishDate | 2024-02-01 |
| publisher | Innovative Healthcare Institute |
| record_format | Article |
| series | Journal of Immunotherapy and Precision Oncology |
| spelling | doaj.art-3cb038dcb4134b309adfab6871b4ee9e2024-02-12T16:45:28ZengInnovative Healthcare InstituteJournal of Immunotherapy and Precision Oncology2666-23452590-017X2024-02-0171677210.36401/JIPO-23-19i2590-017X-7-1-67Sustained Clinical Response to Immunotherapy Followed by BET Inhibitor in a Patient with Unresectable Sinonasal NUT CarcinomaHarriet Herbison0Sidney Davis1David Nickless2Andrew Haydon3Malaka Ameratunga41 Department of Medical Oncology, Monash Health, Clayton, Victoria, Australia2 Department of Radiation Oncology, The Alfred Hospital, Melbourne, Victoria, Australia3 Department of Anatomical Pathology, Cabrini Pathology, Melbourne, Victoria, Australia4 Department of Medical Oncology, The Alfred Hospital, Melbourne, Victoria, Australia4 Department of Medical Oncology, The Alfred Hospital, Melbourne, Victoria, AustraliaNUT carcinomas (NCs) are a group of rare tumors that can occur anywhere in the body and are defined by the fusion of the nuclear protein in testis (NUTM1) resulting in increased transcription of proto-oncogenes. NCs have a poor prognosis that varies according to the site of origin with an urgent need to develop new treatment strategies. Case reports on immunotherapy in pulmonary NC have been published, and bromodomain and extraterminal (BET) inhibitors have shown activity in NC in phase I/II trials. We present the case of a 27-year-old woman with an unresectable sinonasal NC who had a sustained clinical response to both immunotherapy and BET inhibitor therapy. This is the first reported case of immunotherapy in sinonasal NC, and it highlights the different responses to a range of treatments including BET inhibitor therapy. This case supports the theory that NCs arising from different primary sites have differing prognoses.https://jipo.org/doi/pdf/10.36401/JIPO-23-19nut carcinomabet inhibitorradiationimmunotherapy |
| spellingShingle | Harriet Herbison Sidney Davis David Nickless Andrew Haydon Malaka Ameratunga Sustained Clinical Response to Immunotherapy Followed by BET Inhibitor in a Patient with Unresectable Sinonasal NUT Carcinoma Journal of Immunotherapy and Precision Oncology nut carcinoma bet inhibitor radiation immunotherapy |
| title | Sustained Clinical Response to Immunotherapy Followed by BET Inhibitor in a Patient with Unresectable Sinonasal NUT Carcinoma |
| title_full | Sustained Clinical Response to Immunotherapy Followed by BET Inhibitor in a Patient with Unresectable Sinonasal NUT Carcinoma |
| title_fullStr | Sustained Clinical Response to Immunotherapy Followed by BET Inhibitor in a Patient with Unresectable Sinonasal NUT Carcinoma |
| title_full_unstemmed | Sustained Clinical Response to Immunotherapy Followed by BET Inhibitor in a Patient with Unresectable Sinonasal NUT Carcinoma |
| title_short | Sustained Clinical Response to Immunotherapy Followed by BET Inhibitor in a Patient with Unresectable Sinonasal NUT Carcinoma |
| title_sort | sustained clinical response to immunotherapy followed by bet inhibitor in a patient with unresectable sinonasal nut carcinoma |
| topic | nut carcinoma bet inhibitor radiation immunotherapy |
| url | https://jipo.org/doi/pdf/10.36401/JIPO-23-19 |
| work_keys_str_mv | AT harrietherbison sustainedclinicalresponsetoimmunotherapyfollowedbybetinhibitorinapatientwithunresectablesinonasalnutcarcinoma AT sidneydavis sustainedclinicalresponsetoimmunotherapyfollowedbybetinhibitorinapatientwithunresectablesinonasalnutcarcinoma AT davidnickless sustainedclinicalresponsetoimmunotherapyfollowedbybetinhibitorinapatientwithunresectablesinonasalnutcarcinoma AT andrewhaydon sustainedclinicalresponsetoimmunotherapyfollowedbybetinhibitorinapatientwithunresectablesinonasalnutcarcinoma AT malakaameratunga sustainedclinicalresponsetoimmunotherapyfollowedbybetinhibitorinapatientwithunresectablesinonasalnutcarcinoma |